Amendment No. 1 to Software License AgreementSoftware License Agreement • May 1st, 2013 • Zalicus Inc. • Pharmaceutical preparations
This Amendment (the “Amendment”), dated April 30, 2013 (the “Amendment Effective Date”), amends the Software License Agreement, effective as of May 1, 2009 (the “Software License Agreement”), by and between Zalicus Inc. (formerly known as CombinatoRx, Incorporated), a Delaware corporation with an office at 245 First Street, Third Floor, Cambridge, Massachusetts 02142 (“Zalicus”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation with an office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”). Novartis and Zalicus are each separately referred to as a “Party” and are collectively referred to as the “Parties”. Capitalized terms not otherwise defined in this Amendment have the meaning set forth in the Software License Agreement.
Amendment No. 2Research Collaboration and License Agreement • May 1st, 2013 • Zalicus Inc. • Pharmaceutical preparations
This Amendment No. 2 (the “Amendment”), dated April 30, 2013 (the “Amendment Effective Date”), amends the Research Collaboration and License Agreement, effective as of May 1, 2009, amended as of April 12, 2012 (the “Research Agreement”), by and between Zalicus Inc. (formerly known as CombinatoRx, Incorporated), a Delaware corporation with an office at 245 First Street, Third Floor, Cambridge, Massachusetts 02142 (“Zalicus”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation with an office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”). Novartis and Zalicus are each separately referred to as a “Party” and are collectively referred to as the “Parties”. Capitalized terms not otherwise defined in this Amendment have the meaning set forth in the Research Agreement.
